Guideline-directed medical therapy and dose titration are essential to improving outcomes in heart failure with reduced or mildly reduced ejection fraction.According to the CDC, 6.7 million U.S.

Patients with newly diagnosed heart failure with reduced ejection fraction (HFrEF) commonly have improvements in their LVEF, but that doesn’t mean they can let their guard down, data from a large ...

Patients with heart failure with preserved ejection fraction (HFpEF) present with non-specific symptoms, but are common in primary care. Most patients are not diagnosed with HFpEF until they develop ...

The role of ACE inhibitors in the management of HFPEF is less significant compared with their role in the management of heart failure with left ventricular systolic dysfunction. For patients with ...

Improvements in optimal medical therapy for patients with heart failure with reduced ejection fraction (HFrEF) have helped reduce the risk of sudden cardiac death (SCD)—in the modern era, though, just ...

The American Heart Association, a relentless force changing the future of health for everyone everywhere, is launching a new initiative to improve in-hospital care for people with heart failure with ...

San Francisco, CA, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Eko, a digital health company applying artificial intelligence (AI) in the fight against heart disease, today announced the U.S. Food and Drug ...

The SGLT2 inhibitor medicines have changed how heart failure is managed. Originally sodium-glucose cotransporter 2 (SGLT2) inhibitors were used to lower blood sugar levels in people who have type 2 ...

Optimal NT-proBNP cut-off values increased progressively with advancing CKD: 694 pg/mL in Stage 3a, 1,452 pg/mL in Stage 3b, 1,562 pg/mL in Stage 4, and 2,121 pg/mL in Stage 5. After adjusting for ...

Objective: To provide an overview of heart failure with preserved ejection fraction (HFPEF), as well as its pathophysiology, diagnosis, and clinical evidence regarding its pharmacologic management.